Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations
December 23rd 2022Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.
Read More
Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
December 16th 2022Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.
Read More